Modular Medical Reports $7.36 Million Net Loss and Deteriorating Cash Position

Modular Medical, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending December 31, 2025. The company recorded a net loss of $7.36 million for the three months ended December 31, 2025, compared to a loss of $4.80 million in the same period the previous year. For the nine months ending December 31, 2025, the net loss was $21.85 million, up from $13.90 million in the prior year. The increase in losses is attributed to rising operating expenses, which totaled $7.24 million for the quarter, a 49% increase from $4.85 million in the prior year, driven primarily by higher research and development costs.

The company’s cash position has also deteriorated, with cash and cash equivalents dropping to $2.94 million as of December 31, 2025, down from $13.10 million at the end of March 2025. This decline in liquidity raises concerns about the company's ability to sustain operations, as it has not yet generated revenue from its insulin delivery systems. Modular Medical's accumulated deficit has now reached $106.61 million, reflecting ongoing financial strain.

In terms of strategic developments, Modular Medical has made progress in its product offerings. The company received FDA clearance for its MODD1 insulin pump in September 2024 and has since announced plans to commercialize a next-generation product, the Pivot pump. The company submitted a 510(k) premarket notification for the Pivot in November 2025 and aims to launch it pending regulatory approval. However, the company has indicated that it will not commercialize the MODD1 product, focusing instead on the Pivot.

Operationally, Modular Medical has expanded its workforce, increasing its employee count to 69 as of December 31, 2025, up from 48 a year earlier. This growth includes a significant increase in research and development personnel, which rose to 58 from 44. The company is also actively seeking additional financing to support its operations, having raised approximately $4.8 million from a public offering in December 2025 and $4 million from a warrant inducement offering in September 2025. Despite these efforts, the company has expressed substantial doubt about its ability to continue as a going concern, emphasizing the need for further capital to sustain its operations and product development initiatives.

Looking ahead, Modular Medical's management has indicated that the company expects to continue incurring operating losses as it invests in the commercialization of its products. The company is focused on obtaining regulatory approvals and enhancing its product offerings, but it acknowledges that without sufficient capital, it may need to curtail its operations significantly. The outlook remains uncertain as the company navigates these financial challenges while striving to bring its innovative insulin delivery systems to market.